Williamson Neil R, Fineran Peter C, Gristwood Tamzin, Chawrai Suresh R, Leeper Finian J, Salmond George P C
University of Cambridge, Department of Biochemistry, Tennis Court Road, UK.
Future Microbiol. 2007 Dec;2(6):605-18. doi: 10.2217/17460913.2.6.605.
Bacterial prodiginines are a family of red-pigmented, tripyrrolic compounds that display numerous biological activities, including antibacterial, antifungal, antiprotozoal, antimalarial, immunosuppressive and anticancer properties. Recently, significant progress has been made in understanding the biosynthesis and regulation of bacterial prodiginines. An understanding of the biosynthesis of prodiginines will allow engineering of bacterial strains capable of synthesizing novel prodiginines through rational design and mutasynthesis experiments. Bacterial prodiginines and synthetic derivatives are effective proapoptotic agents with multiple cellular targets, and they are active against numerous cancer cell lines, including multidrug-resistant cells, with little or no toxicity towards normal cell lines. A synthetic derivative, GX15-070 (Obatoclax), developed through structure-activity relationship studies of the pyrrolic ring A of GX15, is in multiple Phase I and II clinical trials in both single and dual-agent studies to treat different types of cancer. Therefore, prodiginines have real therapeutic potential in the clinic.
细菌灵菌红素是一类红色的、三吡咯化合物,具有多种生物活性,包括抗菌、抗真菌、抗原虫、抗疟疾、免疫抑制和抗癌特性。最近,在了解细菌灵菌红素的生物合成和调控方面取得了重大进展。对灵菌红素生物合成的了解将有助于通过合理设计和突变合成实验构建能够合成新型灵菌红素的菌株。细菌灵菌红素及其合成衍生物是具有多个细胞靶点的有效促凋亡剂,它们对包括多药耐药细胞在内的多种癌细胞系具有活性,对正常细胞系几乎没有或没有毒性。通过对GX15的吡咯环A进行构效关系研究开发的一种合成衍生物GX15-070(Obatoclax),正在进行多项I期和II期临床试验,包括单药和双药研究,以治疗不同类型的癌症。因此,灵菌红素在临床上具有真正的治疗潜力。